Mason, OH, United States of America

Adam Wardak

This inventor holds 1 USPTO granted patent. Top assignee: The Procter Gamble Company. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adam Wardak: Innovator in Medicinal Formulations

Introduction

Adam Wardak is a notable inventor based in Mason, OH (US). He has made significant contributions to the field of medicinal formulations, particularly with his innovative designs that enhance the delivery of liquid medications. His work is recognized for its practicality and effectiveness in improving patient care.

Latest Patents

Adam holds a patent for a "Dose cup for liquid medicinal formulations." This invention is designed to facilitate the accurate measurement and administration of liquid medications, ensuring that patients receive the correct dosage. His patent portfolio includes 1 patent, showcasing his commitment to advancing healthcare solutions.

Career Highlights

Adam is currently employed at The Procter & Gamble Company, where he applies his expertise in product development and innovation. His role involves collaborating with teams to create effective solutions that meet consumer needs. His work at such a prestigious company highlights his skills and dedication to the field.

Collaborations

Throughout his career, Adam has worked alongside talented colleagues, including Erica Takahashi and Janet Luong. These collaborations have allowed him to leverage diverse perspectives and expertise, further enhancing the quality of his inventions.

Conclusion

Adam Wardak is a distinguished inventor whose contributions to medicinal formulations have made a positive impact on healthcare. His innovative spirit and dedication to improving patient outcomes are evident in his work and collaborations.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…